Coloplast A/S

Copenhagen Stock Exchange COLO-B.CO

Coloplast A/S Price to Book Ratio (P/B) on January 14, 2025: 9.18

Coloplast A/S Price to Book Ratio (P/B) is 9.18 on January 14, 2025, a -14.87% change year over year. Price to book ratio compares the stock price to the book value per share; above 1 indicates market values company more than its book value.
  • Coloplast A/S 52-week high Price to Book Ratio (P/B) is 13.13 on March 08, 2024, which is 43.02% above the current Price to Book Ratio (P/B).
  • Coloplast A/S 52-week low Price to Book Ratio (P/B) is 9.05 on January 02, 2025, which is -1.40% below the current Price to Book Ratio (P/B).
  • Coloplast A/S average Price to Book Ratio (P/B) for the last 52 weeks is 11.34.
Key data
Date Price to Book Ratio (P/B) Dividend Yield Free Cash Flow Yield Price to Earnings Ratio (P/E)
Market news
Loading...
Copenhagen Stock Exchange: COLO-B.CO

Coloplast A/S

CEO Mr. Kristian Villumsen
IPO Date Jan. 2, 2000
Location Denmark
Headquarters Holtedam 1-3
Employees 16,639
Sector Health Care
Industries
Description

Coloplast A/S develops and sells intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Interventional Urology, Voice and Respiratory Care, and Wound & Skin Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, hand cleanser, and odor control products, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, it offers voice and respiratory products, including medical devices for neck stoma under the Provox brand; and products for tracheostoma under the TRACOE brand. The company was founded in 1954 and is headquartered in Humlebæk, Denmark.

Similar companies

DSV.CO

DSV A/S

USD 204.21

-1.25%

AMBU-B.CO

Ambu A/S

USD 18.73

1.26%

GN.CO

GN Store Nord A/S

USD 17.06

1.00%

StockViz Staff

January 15, 2025

Any question? Send us an email